Zenas BioPharma, Inc. Annual Report Summary

Dive into Zenas BioPharma, Inc.'s strategic direction and performance for the fiscal year ending December 31, 2025. As an emerging growth company and smaller reporting company, Zenas leverages reporting flexibilities to focus intently on advancing its pipeline rather than generating immediate commercial revenue.

Business Overview (what the company does): Zenas BioPharma is a clinical-stage biopharmaceutical company focused on developing innovative therapies for immunology and inflammation (I&I) diseases. We are advancing a pipeline of product candidates designed to treat conditions where the immune system malfunctions, such as autoimmune disorders. Zenas common stock trades on the Nasdaq Global Select Market under the ticker ZBIO. As of June 30, 2025, the market value of our common stock held by non-affiliates stood at approximately $259.3 million, with shares priced around $9.69. The company had 57,361,260 shares outstanding as of February 28, 2026.

Financial Performance (revenue, profit, year-over-year changes): Zenas BioPharma significantly invested in its research and development (R&D) pipeline throughout the fiscal year, reflecting its clinical-stage focus.

• Revenue: Consistent with our clinical-stage status, Zenas generated minimal revenue, primarily from collaboration agreements totaling approximately $5.2 million (an increase from $3.8 million last year).
• Research & Development (R&D) Expenses: R&D expenses, the primary driver of operational costs, increased to approximately $125.7 million (up from $98.5 million in the prior year) as we advanced our lead product candidates through clinical trials.
• General & Administrative (G&A) Expenses: General and administrative (G&A) expenses reached approximately $35.1 million (compared to $28.9 million last year), supporting corporate operations and infrastructure.
• Net Loss: Reflecting substantial R&D investments, Zenas reported a net loss of approximately $155.4 million for the year, widening from a net loss of $120.1 million in the previous year.
• Cash Burn: Our operational cash burn for the fiscal year totaled approximately $145 million.

Key Achievements and Challenges: The past year marked significant progress across Zenas's clinical pipeline.

• Pipeline Advancement: We successfully advanced our lead product candidate, ZB001, into Phase 2b clinical trials for Systemic Lupus Erythematosus, demonstrating promising early-stage data.
• Orphan Drug Designation: Zenas secured Orphan Drug Designation from the FDA for ZB002 to treat a rare autoimmune disease. This designation offers significant benefits, including potential market exclusivity post-approval, tax credits for clinical research, and a waiver of the New Drug Application (NDA) fee, substantially de-risking this specific program's development.
• Strategic Partnerships: We entered a new research collaboration with a major academic institution to explore novel targets in I&I.
• Challenges: Despite these achievements, Zenas faces significant challenges, including increased R&D costs and the inherent risks of clinical trial delays or unexpected results. The highly competitive I&I landscape also demands continuous innovation and differentiation.

Financial Health (debt, cash, liquidity):

• Cash Position: At fiscal year-end, Zenas held cash, cash equivalents, and marketable securities totaling approximately $210.5 million (down from $350.2 million last year). This portfolio includes investments in money market funds, U.S. government securities, and corporate debt.
• Debt Financing: To bolster our financial runway and support ongoing clinical development, Zenas secured a debt facility in early 2026 for up to $100 million. We drew an initial tranche of $40 million, with the remaining $60 million available in future tranches contingent on achieving specific clinical and operational milestones. This debt primarily funds the continued advancement of our late-stage clinical programs.
• Liquidity: Based on current projections and recent debt financing, management estimates our existing cash and investments, combined with available debt tranches, will fund operations into late 2027. However, future capital raises will likely be necessary to bring product candidates to market.

Risk Factors (key risks): Investing in Zenas BioPharma carries significant risks, typical of the biotechnology sector:

• Clinical Trial Success: The success of our product candidates remains highly uncertain, depending on positive outcomes from ongoing and future clinical trials. Failure at any stage could significantly impact Zenas's valuation.
• Regulatory Approval: Even with positive trial data, regulatory approval from agencies like the FDA is not guaranteed. The approval process is lengthy, complex, and subject to evolving standards.
• Commercialization: If approved, Zenas faces challenges in successfully commercializing its products, including achieving market acceptance, navigating pricing pressures, and overcoming competition.
• Funding Needs: We will require substantial additional capital to complete clinical development and commercialize our product candidates. Future financing may dilute existing shareholders.
• Intellectual Property: Protecting our intellectual property is critical; any challenges to patents could negatively impact our competitive position.
• Competition: The I&I therapeutic area is highly competitive, with numerous established pharmaceutical companies and emerging biotechs developing similar or alternative treatments.

Competitive Position: Zenas differentiates itself by focusing on novel mechanisms of action and targeting underserved patient populations within the I&I space. Our strategy involves rigorous clinical development, seeking orphan drug designations where applicable, and exploring strategic partnerships for potential commercialization to maximize market reach.

Future Outlook (guidance, strategy): Zenas BioPharma's future hinges on successfully executing our clinical development programs. We remain focused on advancing our lead candidates through pivotal trials, securing additional orphan drug designations, and exploring potential collaborations to accelerate commercialization. Key milestones for the upcoming year include reporting top-line data from the Phase 2b trial of ZB001 and initiating a Phase 3 study for ZB002. The growing I&I market, driven by the increasing prevalence of autoimmune diseases and demand for more effective treatments, presents significant commercial opportunities for Zenas if our pipeline proves successful.